Evidence map›Paper›PMID 30071836›Full record

ArticleBMC infectious diseases2018

Case report: persistently seronegative neuroborreliosis in an immunocompromised patient.

A Wagemakers, M C Visser, B de Wever, J W Hovius, N W C J van de Donk, E J Hendriks, L Peferoen, F F Muller, C W Ang

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. An unexpected case of Borrelia garinii liver infection.Annals of clinical microbiology and antimicrobials · 2022
    Article
  7. Article
  8. Laboratory Diagnosis of Lyme Borreliosis.Clinical microbiology reviews · 2021
    Review
  9. Article
  10. Under-Detection of Lyme Disease in Canada.Healthcare (Basel, Switzerland) · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

A WagemakersDepartment of medical microbiology, VU medical center, De Boelelaan 1117, Amsterdam, 1081, HV, The Netherlands. a.wagemakers@vumc.nl.ORCID 0000-0001-9632-7830
M C VisserDepartment of neurology, VU medical center, De Boelelaan 1117, Amsterdam, 1081, HV, The Netherlands.
B de WeverDepartment of medical microbiology, Academic medical center, Meibergdreef 9, Amsterdam, 1105, AZ, The Netherlands.
J W HoviusDepartment of internal medicine/Amsterdam multidisciplinary Lyme center, Academic medical center, Meibergdreef 9, Amsterdam, 1105, AZ, The Netherlands.
N W C J van de DonkDepartment of hematology, VU medical center, De Boelelaan 1117, Amsterdam, 1081, HV, The Netherlands.
E J HendriksDepartment of radiology and nuclear medicine, VU medical center, De Boelelaan 1117, Amsterdam, 1081, HV, The Netherlands.
L PeferoenDepartment of pathology, VU medical center, De Boelelaan 1117, Amsterdam, 1081, HV, The Netherlands.
F F MullerDepartment of neurology, VU medical center, De Boelelaan 1117, Amsterdam, 1081, HV, The Netherlands.
C W AngDepartment of medical microbiology, VU medical center, De Boelelaan 1117, Amsterdam, 1081, HV, The Netherlands.
Amsterdam UMC Location Vrije Universiteit Amsterdam · NLAmsterdam UMC Location University of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfection with Borrelia burgdorferi sensu lato complex (B. b. sl) spirochetes can cause Lyme borreliosis, manifesting as localized infection (e.g. erythema migrans) or disseminated disease (e.g. Lyme neuroborreliosis). Generally, patients with disseminated Lyme borreliosis will produce an antibody response several weeks post-infection. So far, no case of neuroborreliosis has been described with persistently negative serology one month after infection. CASE PRESENTATION: We present a patient with a history of Mantle cell lymphoma and treatment with R-CHOP (rituximab, doxorubicine, vincristine, cyclofosfamide, prednisone), with a meningo-encephalitis, who was treated for a suspected lymphoma relapse. However, no malignant cells or other signs of malignancy were found, and microbial tests did not reveal any clues, including Borrelia serology. He did not recall being bitten by ticks, and a Borrelia PCR on CSF was negative. After spontaneous improvement of symptoms, he was discharged without definite diagnosis. Several weeks later, he was readmitted with a relapse of symptoms of meningo-encephalitis. This time however, a Borrelia PCR on CSF was positive, confirmed by two independent laboratories, and the patient received ceftriaxone upon which he partially recovered. Interestingly, during the diagnostic process of this exceptionally difficult case, a variety of different serological assays for Borrelia antibodies remained negative. Only P41 (flagellin) IgG was detected by blot and the Liaison IgG became equivocal 2 months after initial testing.

conclusionsTo the best of our knowledge this is the first case of neuroborreliosis that is seronegative on repeated sera and multiple test modalities. This unique case demonstrates the difficulty to diagnose neuroborreliosis in severely immunocompromised patients. In this case, a delay in diagnosis was caused by broad differential diagnosis, an absent known history of tick bites, negative serology and the low sensitivity of PCR on CSF. Therefore, awareness of the diagnostic limitations to detect Borrelia infection in this specific patient category is warranted.

Indexed as

Immunocompromised HostLyme NeuroborreliosisLymphoma, Mantle-CellHumansMaleBorreliaDiagnosisImmunocompromisedNeuroborreliosisRituximabSerology

Identifiers

PMID30071836
PMCPMC6090844
OpenAlexW2885076285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.